PepsiCo, Inc. 10-Q Summary: Q1 2025
Business Context and Reporting Period
This filing covers the 12-week period ended March 22, 2025. PepsiCo, Inc. is a large accelerated filer reporting on a 52/53-week fiscal year. Effective Q1 2025, the company realigned its reportable segments to six categories: PepsiCo Foods North America (PFNA), PepsiCo Beverages North America (PBNA), International Beverages Franchise (IB Franchise), Europe, Middle East and Africa (EMEA), Latin America Foods (LatAm Foods), and Asia Pacific Foods.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Net Revenue | $17,919 million | $18,250 million | (2)% |
| Operating Profit | $2,583 million | $2,717 million | (5)% |
| Operating Margin | 14.4% | 14.9% | (0.5) pts |
| Net Income Attributable to PepsiCo | $1,834 million | $2,042 million | (10)% |
| Diluted EPS | $1.33 | $1.48 | (10)% |
| Net Cash Used for Operating Activities | $(973) million | $(1,041) million | Improvement |
| Free Cash Flow (Non-GAAP) | $(1,444) million | $(1,648) million | Improvement |
| Total Debt (Short + Long Term) | $48,518 million | $44,306 million (est.) | Increased |
| Cash and Cash Equivalents | $8,268 million | $8,505 million (Dec 2024) | Decreased |
Note: Q1 2024 operating profit was impacted by a $167 million product recall charge in the prior year which is not present in Q1 2025.
Material Changes vs. Prior Period
- Revenue Decline: Reported net revenue decreased 2% due to a 2% decline in organic volume and a 3% unfavorable impact from foreign exchange translation. This was partially offset by 3% effective net pricing.
- Profitability Pressure: Operating profit declined 5%. Drivers included higher commodity costs (3% impact), unfavorable foreign exchange (4% impact), and operating cost increases. These were partially offset by productivity savings and lower advertising expenses.
- Segment Performance:
- PFNA: Revenue down 1%; Operating profit up 2% (benefited by absence of prior-year recall charges).
- PBNA: Revenue flat; Operating profit down 10% due to higher restructuring costs and operating expenses.
- LatAm Foods: Revenue down 12% and Operating profit down 18%, heavily impacted by the weakening Mexican peso.
- EMEA: Revenue down 2% but Operating profit up 3%, driven by pricing and productivity despite high commodity costs.
- Restructuring: The company incurred $213 million in restructuring and impairment charges related to the 2019 Productivity Plan, compared to $96 million in the prior year.
Guidance, Outlook, and Risks
- Capital Allocation: PepsiCo announced a 5% increase in its annualized dividend to $5.69 per share. The company expects to return approximately $8.6 billion to shareholders in 2025 ($7.6 billion in dividends and $1.0 billion in share repurchases).
- Acquisitions: Completed the acquisition of Siete for $1.2 billion. Entered a definitive agreement to acquire poppi for $1.95 billion, subject to regulatory approval.
- Productivity Plan: The 2019 Productivity Plan has been extended through 2030. Total expected pre-tax charges are approximately $6.15 billion; $2.8 billion has been incurred to date.
- Risks:
- Geopolitical & FX: Continued volatility in international markets (Russia, Middle East, Latin America) and unfavorable currency translation (Mexican peso, Egyptian pound) remain key risks.
- Commodities & Tariffs: Rising input costs and potential tariff impacts on supply chains are monitored closely.
- Taxation: Implementation of the OECD global minimum tax (15%) is expected by end of 2025 and may increase tax provisions.
Investor Verification Checklist
- Verify the impact of the $1.95 billion poppi acquisition on future cash flows and integration costs.
- Monitor the execution of the extended 2019 Productivity Plan and the remaining $3.35 billion in expected pre-tax charges.
- Assess the sustainability of organic volume growth given the reported 2% decline in Q1 2025.
- Review the exposure to foreign exchange rates, particularly the Mexican peso and Russian ruble, which significantly impacted Q1 results.
- Confirm the timeline and regulatory approval status for the poppi acquisition.